Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system

Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins

(2016) L. Wagner et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

CD26/dipeptidylpeptidase IV-chemokine interactions: double-edged regulation of inflammation and tumor biology

(2016) Anneleen Mortier et al.   JOURNAL OF LEUKOCYTE BIOLOGY

The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis

(2015) Basem M. Mishriky et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

High expression of CD26 accurately identifies human bacteria-reactive MR1-restricted MAIT cells

(2015) Prabhat K. Sharma et al.   IMMUNOLOGY

Proteolytic degradation of neuropeptide Y (NPY) from head to toe: Identification of novel NPY-cleaving peptidases and potential drug interactions in CNS and Periphery

(2015) Leona Wagner et al.   JOURNAL OF NEUROCHEMISTRY

The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis

(2015) Yannick Waumans et al.   Frontiers in Immunology

DPP4 in diabetes

(2015) Diana Röhrborn   Frontiers in Immunology

Human treg cells are characterized by low/negative CD6 expression

(2014) Carlos A. Garcia Santana et al.   CYTOMETRY PART A

Substance P Increases Sympathetic Activity During Combined Angiotensin-Converting Enzyme and Dipeptidyl Peptidase-4 Inhibition

(2014) Jessica K. Devin et al.   HYPERTENSION

Inhibition of CD26/Dipeptidyl Peptidase IV Enhances CCL11/Eotaxin-Mediated Recruitment of Eosinophils In Vivo

(2014) U. Forssmann et al.   JOURNAL OF IMMUNOLOGY

Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment

(2014) Amy G. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Soluble DPP4 originates in part from bone marrow cells and not from the kidney

(2014) Zhendi Wang et al.   PEPTIDES

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus Patients with Moderate to Severe Renal Impairment: A Systematic Review and Meta-Analysis

(2014) Dongsheng Cheng et al.   PLoS One

Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oral antihyperglycaemic agents: a systematic review and network meta-analysis

(2014) Andrea C Tricco et al.   BMJ Open

Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors

(2013) A. E. Butler et al.   DIABETES

Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors

(2013) Tatsuhiko Saito et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

DPP4 inhibitor-induced polyarthritis: a report of three cases

(2013) Etienne Crickx et al.   RHEUMATOLOGY INTERNATIONAL

CD26: A negative selection marker for human Treg cells

(2012) Francisco J. Salgado et al.   CYTOMETRY PART A

A Potential Role for Dendritic Cell/Macrophage-Expressing DPP4 in Obesity-Induced Visceral Inflammation

(2012) Jixin Zhong et al.   DIABETES

CD26-mediated co-stimulation in human CD8+T cells provokes effector function via pro-inflammatory cytokine production

(2012) Ryo Hatano et al.   IMMUNOLOGY

Development of structural kidney damage in spontaneously hypertensive rats

(2012) Michael Hultström   JOURNAL OF HYPERTENSION

Human Th17 Cells Express High Levels of Enzymatically Active Dipeptidylpeptidase IV (CD26)

(2012) B. Bengsch et al.   JOURNAL OF IMMUNOLOGY

Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia

(2012) Peter Röhnert et al.   Journal of Neuroinflammation

Serum and CSF soluble CD26 and CD30 concentrations in healthy pediatric surgical outpatients

(2012) W. Delezuch et al.   TISSUE ANTIGENS

Combined atherogenic effects of celiac disease and type 1 diabetes mellitus

(2011) D. Pitocco et al.   ATHEROSCLEROSIS

Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor

(2011) Albert Mas-Vidal et al.   AUSTRALASIAN JOURNAL OF DERMATOLOGY

Effector granules in human T lymphocytes: the luminal proteome of secretory lysosomes from human T cells

(2011) Hendrik Schmidt et al.   Cell Communication and Signaling

Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis

(2011) Zubair Shah et al.   CIRCULATION

Dipeptidyl peptidase IV (DPP4) deficiency increases Th1-driven allergic contact dermatitis

(2011) T. Tasic et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Dipeptidyl Peptidase-4 Inhibition: Linking Chemical Properties to Clinical Safety

(2011) E. Matteucci et al.   CURRENT MEDICINAL CHEMISTRY

Sitagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Psoriasis

(2011) Tatsuya Nishioka et al.   DERMATOLOGY

DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials

(2011) A.J. Scheen   DIABETES & METABOLISM

Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase

(2011) M. J. Willemen et al.   DIABETES CARE

Animal models of asthma: value, limitations and opportunities for alternative approaches

(2011) Anthony M. Holmes et al.   DRUG DISCOVERY TODAY

Pharmacology of Dipeptidyl Peptidase-4 Inhibitors

(2011) Roberta Baetta et al.   DRUGS

Molecular mechanism and structural basis of interactions of dipeptidyl peptidase IV with adenosine deaminase and human immunodeficiency virus type-1 transcription transactivator

(2011) Hua Fan et al.   EUROPEAN JOURNAL OF CELL BIOLOGY

Enhanced ovalbumin-induced airway inflammation in CD26−/−mice

(2011) Shuling Yan et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Development and resolution of colitis in mice with target deletion of dipeptidyl peptidase IV

(2011) Dijana Detel et al.   EXPERIMENTAL PHYSIOLOGY

Neuroimmunomodulative properties of dipeptidyl peptidase IV/CD26 in a TNBS-induced model of colitis in mice

(2011) Lara Baticic et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

The Safety of Incretin-Based Therapies—Review of the Scientific Evidence

(2011) Daniel J. Drucker et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Serum levels of soluble CD26 and CD30 and their clinical significance in patients with rheumatoid arthritis

(2011) Hasan Ulusoy et al.   RHEUMATOLOGY INTERNATIONAL

Dipeptidyl peptidase-IV in synovial fluid and in synovial fluid mononuclear cells of patients with rheumatoid arthritis

(2010) Lucie Sromova et al.   CLINICA CHIMICA ACTA

Reduced airway inflammation in CD26/DPP4-deficient F344 rats is associated with altered recruitment patterns of regulatory T cells and expression of pulmonary surfactant proteins

(2010) A. Schmiedl et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Stimulation of the expression and the enzyme activity of aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 on human renal cell carcinoma cells and renal tubular epithelial cells by T cell-derived cytokines, such as IL-4 and IL-13

(2010) D. RIEMANN et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans

(2010) Annis Marney et al.   HYPERTENSION

Dipeptidyl Peptidase IV Inhibition Alters the Hemodynamic Response to Angiotensin-Converting Enzyme Inhibition in Humans With the Metabolic Syndrome

(2010) Edwin K. Jackson   HYPERTENSION

Fibroblast activation protein expression in Crohnʼs disease strictures

(2010) Laura Rovedatti et al.   INFLAMMATORY BOWEL DISEASES

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

(2010) S. S. Engel et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

The dimeric transmembrane domain of prolyl dipeptidase DPP-IV contributes to its quaternary structure and enzymatic activities

(2010) Kuei-Min Chung et al.   PROTEIN SCIENCE

IL-17 and Th17 Cells

(2009) Thomas Korn et al.   Annual Review of Immunology

Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP

(2009) Rolf Mentlein   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Blockade of CD26-mediated T cell costimulation with soluble caveolin-1-Ig fusion protein induces anergy in CD4 + T cells

(2009) Kei Ohnuma et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses

(2009) Kalpit A Vora et al.   BMC IMMUNOLOGY

On the origin of serum CD26 and its altered concentration in cancer patients

(2009) Oscar J. Cordero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Airway-specific recruitment of T cells is reduced in a CD26-deficient F344 rat substrain

(2009) J. Schade et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Phenotyping of congenic dipeptidyl peptidase 4 (DP4) deficient Dark Agouti (DA) rats suggests involvement of DP4 in neuro-, endocrine, and immune functions

(2009) Nadine Frerker et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Dipeptidyl Peptidase-4 (CD26): Knowing the Function before Inhibiting the Enzyme

(2009) E. Matteucci et al.   CURRENT MEDICINAL CHEMISTRY

CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL

(2009) Lilla Cro et al.   HEMATOLOGICAL ONCOLOGY

Transferred T cells preferentially adhere in the BALT of CD26-deficient recipient lungs during asthma

(2009) Jutta Schade et al.   IMMUNOBIOLOGY

Natural killer cell cytotoxicity: how do they pull the trigger?

(2009) Nicola J. Topham et al.   IMMUNOLOGY

A CD26-Controlled Cell Surface Cascade for Regulation of T Cell Motility and Chemokine Signals

(2009) Z. Liu et al.   JOURNAL OF IMMUNOLOGY

Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?

(2009) Roger Yazbeck et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

CD26/dipeptidyl peptidase 4-deficiency alters thymic emigration patterns and leukcocyte subsets in F344-rats age-dependently

(2008) C. Klemann et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

(2008) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice

(2008) Roger Yazbeck   Frontiers in Bioscience-Landmark

Inflammatory bowel diseases: multiple benefits from therapy with dipeptidyl- and alanyl-aminopeptidase inhibitors

(2008) Ute Bank   Frontiers in Bioscience-Landmark

Differential expression of CD26 on virus-specific CD8+T cells during active, latent and resolved infection

(2008) Chris C. Ibegbu et al.   IMMUNOLOGY

Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function

(2008) Kei Ohnuma et al.   TRENDS IN IMMUNOLOGY

EFFECTS OF DIPEPTIDYL PEPTIDASE IV INHIBITION ON ARTERIAL BLOOD PRESSURE

(2007) Edwin K Jackson et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis

(2007) Dirk Reinhold   Frontiers in Bioscience-Landmark

Is Dipeptidylpeptidase IV the Missing Link in Angiotensin-Converting Enzyme Inhibitor–Induced Angioedema?

(2007) Eric Grouzmann et al.   HYPERTENSION